Together, these results demonstrate that dual targeting of HIF1α and NT5E in EAC cells not only impacts tumor cell viability but also disrupts key extracellular pathways driving immune evasion, angiogenesis, and metastatic potential, underscoring the multifaceted therapeutic potential of this combinatorial approach in esophageal adenocarcinoma. The gene discussed is HIF1A; the disease is neoplasm.